The U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab), in combination with chemotherapy, to treat people with advanced triple-negative breast cancer (TNBC) and at least 10% of tumor cells positive for PD-L1. The indication includes patients with locally recurrent and inoperable or metastatic tumors, not previously treated with chemotherapy. Tumor PD-L1 status will be determined by the PD-L1 IHC 22C3 pharmDx test (marketed by Dako, a subsidiary of Agilent), which was approved simultaneously by…
You must be logged in to read/download the full post.
The post FDA Approves Keytruda-chemo Combo for Advanced TNBC Positive for PD-L1 appeared first on BioNewsFeeds.